Oral composition

Abstract

Provided is an oral composition in which unpleasant odor of branched fatty acids having 6 or less carbon atoms is suppressed. This oral composition contains the following components (A) and (B): (A) 0.01 ppm by mass or more of a branched fatty acid having 6 or less carbon atoms; (B) 0.05 ppm by mass or more of at least one monoterpene alcohol selected from the group consisting of linalool and geraniol.

Description

Technical Field

[0001] The present invention relates to an oral composition, an inhibitor of the unpleasant odor of a branched fatty acid having 6 or less carbon atoms, and a method for inhibiting an unpleasant odor. Background Art

[0002] Short-chain fatty acids having a branch with 6 or less carbon atoms exist naturally in the form of free or esters as components of essential oils. This fatty acid is used as an aromatic component at an extremely low concentration in fragrances. In addition, for branched short-chain fatty acids, it is known that they are produced by intestinal bacteria in the human large intestine in the same manner as straight-chain short-chain fatty acids, and although many of their physiological functions are still unclear, they are considered to have effects similar to those of straight-chain short-chain fatty acids. On the other hand, branched short-chain fatty acids are known as causative substances of unpleasant odors generated from various parts of the body and off-odors present in foods, and due to their unique odor, it is desired to inhibit them.

[0003] Linalool and geraniol are a kind of monoterpenoid alcohols and are widely used in the preparation of various flower essential oils, or in cosmetic fragrances and food fragrances. In the prior art, it has been reported that by adding linalool and geraniol to a beer-flavored beverage, a beer-flavored beverage having the aroma of citrus and suppressing the deterioration of flavor and the generation of unpleasant aroma due to storage can be obtained (Patent Document 1); and that by adding linalool and geraniol to a foaming beverage, a beverage having an unprecedented pleasant aroma can be obtained (Patent Document 2), etc.

[0004] In addition, a technique for enhancing the flavor of a beverage by adding a lower fatty acid or its ester in the production of a beverage containing linalool and geraniol has been reported (Patent Document 3). However, it is not known what effect linalool and geraniol have on the unpleasant odor of branched short-chain fatty acids.

[0005] (Patent Document 1) Japanese Patent Laid-Open No. 2020-96569

[0006] (Patent Document 2) Japanese Patent Laid-Open No. 2017-143808

[0007] (Patent Document 3) Japanese Patent Laid-Open No. 2016-25866 Summary of the Invention

[0008] The present invention relates to the following 1) to 3).

[0009] 1) An oral composition containing the following components (A) and (B),

[0010] (A) A branched fatty acid having 6 or less carbon atoms: 0.01 mass ppm or more;

[0011] (B) At least one monoterpenoid alcohol selected from linalool and geraniol: 0.05 mass ppm or more.

[0012] 2) An inhibitor for the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms, wherein at least one monoterpenoid alcohol selected from linalool and geraniol is used as an active ingredient.

[0013] 3) A method for inhibiting the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms, wherein at least one monoterpenoid alcohol selected from linalool and geraniol coexists with the branched-chain fatty acid having 6 or less carbon atoms. Detailed implementation mode

[0014] The present invention provides an oral composition in which the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms is inhibited, an inhibitor for the unpleasant odor, and a method for inhibiting the unpleasant odor.

[0015] The present inventors repeatedly conducted intensive studies and found that linalool and / or geraniol has the effect of inhibiting the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms, and an oral composition in which the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms is inhibited can be obtained by containing linalool and / or geraniol.

[0016] According to the present invention, an oral composition in which the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms is inhibited, an inhibitor for the unpleasant odor, and a method for inhibiting the unpleasant odor can be provided.

[0017] [Oral composition]

[0018] The oral composition of the present invention contains a branched-chain fatty acid having 6 or less carbon atoms as component (A). The branched-chain fatty acid has 6 or less carbon atoms, preferably 2 to 6, more preferably 4 or 5, and further preferably 5. The number and position of the branches of the branched-chain fatty acid are not particularly limited, and preferably include an iso-fatty acid having a methyl branch on the second carbon counted from the terminal methyl, and an anteiso-fatty acid having a methyl branch on the third carbon counted from the terminal methyl. The branched-chain fatty acid can be any one of a saturated fatty acid and an unsaturated fatty acid.

[0019] Specific examples of component (A) include, for example, isobutyric acid, isovaleric acid, 2-methylbutyric acid, 4-methylpentanoic acid, 4-methyl-3-pentenoic acid, etc. Among them, from the aspect of easily enjoying the effects of the present invention, one or more selected from isobutyric acid, 2-methylbutyric acid, and isovaleric acid are preferred, and isovaleric acid is further preferred.

[0020] One or more than two kinds of component (A) can be used.

[0021] As component (A), commercially available reagents can be used, or extracts of plants rich in component (A) can be used. In addition, when using a plant extract as component (A), there are no particular limitations on the extraction method and extraction conditions of the plant extract, and known methods can be adopted.

[0022] There are no particular limitations on the plant, as long as it contains component (A), and coffee beans are preferred. The coffee beans are preferably one or more selected from raw coffee beans and lightly roasted coffee beans, and raw coffee beans are further preferred. Here, in this specification, "lightly roasted coffee beans" refers to roasted coffee beans with an L value of 30 or more and 60 or less. From the viewpoints of suppressing the unpleasant odor of component (A) and physiological effects, it is preferably 32 or more, more preferably 34 or more, further preferably 36 or more, further more preferably 38 or more, and further more preferably 40 or more. In addition, there are no particular limitations on the variety and origin of the coffee beans. In addition, in this specification, the "L value" refers to the value obtained by setting black as L value 0 and white as L value 100 and measuring the brightness of roasted coffee beans using a color difference meter.

[0023] The content of component (A) in the oral composition of the present invention is 0.01 mass ppm or more. From the viewpoint of more easily enjoying the effects of the present invention, it is preferably 0.05 mass ppm or more, and further preferably 0.3 mass ppm or more. In addition, from the viewpoint of suppressing the unpleasant odor of component (A), it is preferably 30 mass ppm or less, more preferably 20 mass ppm or less, further preferably 12 mass ppm or less, and further more preferably 8 mass ppm or less. And the content of component (A) in the oral composition of the present invention is 0.01 mass ppm or more, preferably 0.01 - 30 mass ppm, more preferably 0.01 - 20 mass ppm, further preferably 0.05 - 12 mass ppm, and further more preferably 0.3 - 8 mass ppm.

[0024] The content of component (A) can be determined by an analytical method suitable for the sample among commonly known measurement methods. For example, it can be determined by GC / MS (gas chromatograph / mass spectrometry) method or HPLC (high performance liquid chromatography) method. Additionally, analysis can be entrusted to a third-party organization. For analysis by the GC / MS method, it can be entrusted to, for example, the Japan Food Analysis Center, a juridical person. For analysis by the HPLC method, it can be entrusted to, for example, Shimadzu Techno-Research Co., Ltd.

[0025] The oral composition of the present invention contains at least one monoterpenoid alcohol selected from linalool and geraniol as component (B). Both linalool and geraniol are compounds with the molecular formula C 10 H 18 O and are in an isomeric relationship.

[0026] Linalool has optical isomers. Linalool can be either of any optical isomer or a mixture of optical isomers.

[0027] As component (B), commercially available reagents can be used, or it can be contained in the form of a plant extract rich in component (B). Additionally, it can be synthesized by organic synthesis. Moreover, as the plant, appropriate selection can be made within the scope not departing from the gist of the present invention, as long as it contains component (B) and is a plant commonly used in the food and beverage field. Additionally, there are no particular limitations on the extraction method and extraction conditions, and known methods can be adopted.

[0028] For linalool and geraniol, they can be used individually or in combination of two.

[0029] From the viewpoint of suppressing the unpleasant odor of component (A), the content of component (B) in the oral composition of the present invention is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 8 mass ppm or more, further preferably 80 mass ppm or more. Additionally, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, further preferably 1200 mass ppm or less. And the content of component (B) in the oral composition of the present invention is 0.05 mass ppm or more, preferably 0.05 - 3000 mass ppm, more preferably 0.08 - 2000 mass ppm, further preferably 8 - 2000 mass ppm, and further more preferably 80 - 1200 mass ppm.

[0030] When linalool is used as component (B), from the viewpoint of suppressing the unpleasant odor of component (A), in the oral composition, it is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 0.8 mass ppm or more, further preferably 8 mass ppm or more, and further more preferably 80 mass ppm or more. In addition, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, and further preferably 1200 mass ppm or less. And the content of linalool as component (B) in the oral composition of the present invention is 0.05 mass ppm or more, preferably 0.05 to 3000 mass ppm, more preferably 0.08 to 2000 mass ppm, further preferably 0.8 to 2000 mass ppm, further more preferably 8 to 2000 mass ppm, and further more preferably 80 to 1200 mass ppm.

[0031] In addition, when geraniol is used as component (B), from the viewpoint of suppressing the unpleasant odor of component (A), in the oral composition, it is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 8 mass ppm or more, and further preferably 800 mass ppm or more. In addition, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, and further preferably 1500 mass ppm or less. And the content of geraniol as component (B) in the oral composition of the present invention is 0.05 mass ppm or more, preferably 0.05 to 3000 mass ppm, more preferably 0.08 to 2000 mass ppm, further preferably 8 to 2000 mass ppm, and further more preferably 800 to 1500 mass ppm.

[0032] The content of component (B) can be measured by an analytical method suitable for the test sample in commonly known measurement methods. For example, it can be measured by GC / MS method. Specifically, the method described in the following examples can be cited. In addition, when measuring, appropriate treatments can be carried out as needed. For example, the test sample can be freeze-dried to adapt to the detection range of the device, or impurities in the test sample can be removed to adapt to the resolution of the device, etc.

[0033] From the viewpoint of suppressing the unpleasant odor of the inhibitory component (A), the mass ratio [(B) / (A)] of the component (B) to the component (A) in the oral composition of the present invention is preferably 0.003 or more, more preferably 0.15 or more, still more preferably 15 or more, and even more preferably 100 or more. Further, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 20,000 or less, more preferably 16,000 or less, still more preferably 12,000 or less. Moreover, the mass ratio [(B) / (A)] of the component (B) to the component (A) in the present invention is preferably from 0.003 to 20,000, more preferably from 0.15 to 20,000, still more preferably from 15 to 16,000, and even more preferably from 100 to 12,000.

[0034] When linalool is used as the component (B), from the viewpoint of suppressing the unpleasant odor of (A), the mass ratio [linalool / (A)] of linalool to the component (A) in the oral composition of the present invention is preferably 0.003 or more, more preferably 0.15 or more, still more preferably 1 or more, and even more preferably 15 or more, and even more preferably 80 or more, and even more preferably 150 or more. Further, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 20,000 or less, more preferably 16,000 or less, still more preferably 12,000 or less, and even more preferably 6,000 or less, and even more preferably 3,000 or less. Moreover, the mass ratio [linalool / (A)] of the component (B) linalool to the component (A) in the present invention is preferably from 0.003 to 20,000, more preferably from 0.15 to 20,000, still more preferably from 1 to 20,000, and even more preferably from 15 to 16,000, and even more preferably from 80 to 12,000, and even more preferably from 80 to 6,000, and even more preferably from 150 to 3,000.

[0035] In addition, when geraniol is used as component (B), from the viewpoint of suppressing the unpleasant odor of (A), the mass ratio of geraniol to component (A) [geraniol / (A)] in the oral composition of the present invention is preferably 0.003 or more, more preferably 0.15 or more, further preferably 1 or more, still further preferably 15 or more, still further preferably 100 or more. Additionally, from the viewpoint of making the flavor and taste of the oral composition better, it is preferably 20,000 or less, more preferably 16,000 or less, further preferably 12,000 or less, still further preferably 6,000 or less, still further preferably 3,000 or less. Moreover, the mass ratio of component (B) geraniol to component (A) [geraniol / (A)] in the present invention is preferably 0.003 to 20,000, more preferably 0.15 to 20,000, further preferably 1 to 16,000, still further preferably 15 to 12,000, still further preferably 15 to 6,000, still further preferably 100 to 3,000.

[0036] The oral composition of the present invention may contain one or more additives as required, such as sweeteners, acidulants, amino acids, proteins, vitamins, minerals, plant extracts, esters, pigments, emulsifiers, milk components, preservatives, seasonings, quality stabilizers, flavors, etc. The content of the additives can be appropriately set within the range that does not impair the object of the present invention.

[0037] In this specification, an "oral composition" refers to a composition that causes less concern about harm to human health and is specifically ingested orally in normal social life, and it is not limited to classifications such as foods, pharmaceuticals, and quasi-drugs in administrative classifications. Therefore, the oral composition of the present invention refers to a composition that widely includes food products for oral ingestion, such as ordinary foods, health foods (functional food and drink products), health care functional foods (specific health foods, nutritional functional foods, functional labeled foods), quasi-drugs, pharmaceuticals, etc.

[0038] The oral composition of the present invention can be solid or liquid at normal temperature (20°C ± 15°C) and can take an appropriate form. As appropriate forms of the oral composition of the present invention, for example, solid oral compositions and liquid oral compositions can be cited.

[0039] The present invention is preferably used for oral compositions other than coffee beverages. Coffee beverages are beverages that enjoy the unique roasted aroma of roasted coffee beans. Since the unpleasant odor of component (A) can be masked by the roasted odor of the roasted coffee beans, it is considered that coffee beverages are less likely to have the problem of the unpleasant odor of component (A) of the present invention.

[0040] Generally speaking, the content of (C) furfuryl mercaptan (hereinafter, also referred to as "component (C)") in coffee beverages is 0.00006% by mass or more. Therefore, coffee beverages can be clearly distinguished as products different from the oral composition of the present invention. That is, the content of component (C) in the oral composition of the present invention is preferably less than 0.00006% by mass, more preferably less than 0.00003% by mass, further preferably less than 0.00001% by mass, and further particularly preferably substantially free of component (C). Here, in the present specification, the concept of "substantially free of" not only includes the meaning that component (C) is completely absent in the oral composition, but also includes the meaning that its concentration is less than the detection limit. In addition, the content of component (C) can be measured by an analytical method suitable for the sample in commonly known measurement methods. For example, it can be measured by GC / MS method. In addition, during measurement, appropriate treatments can be carried out as needed. For example, the sample can be freeze-dried to adapt to the detection range of the device, or impurities in the sample can be removed to adapt to the resolution of the device, etc.

[0041] In addition, coffee beverages are usually beverages obtained using roasted coffee beans including roasted coffee beans with an L value less than 30. Therefore, the object of the present invention is an oral composition other than the following coffee beverages, which are beverages obtained using roasted coffee beans including roasted coffee beans with an L value preferably less than 30, more preferably less than 32, further preferably less than 34, further more preferably less than 36, further more preferably less than 38, and further particularly preferably less than 40. In addition, the roasted coffee beans can also be roasted coffee beans from which 90% or more of the caffeine has been removed. In addition, the content of the coffee component in the coffee beverage refers to the coffee component extracted or dissolved from roasted coffee beans equivalent to 1 g or more of raw coffee beans contained in 100 g of the net content. In addition, the "raw bean conversion value" means that 1 g of roasted coffee beans is equivalent to 1.3 g of raw coffee beans (recorded on page 421 of the Revised New Edition · Soft Drinks, Supervised Revision: Japan Soft Drink Association, Published: Kourin, December 25, 1989). There is no particular limitation on the type of coffee beverage. For example, it may include coffee beverages and the like defined in Article 2 of the "Fair Competition Code for the Labeling of Coffee Beverages and the Like" revised and implemented on August 19, 2019, that is, "coffee", "coffee beverage", "soft drink containing coffee", and "carbonated drink containing coffee".

[0042] The solid oral composition of the present invention can be made into a solid that can be directly orally ingested. As its form, for example, it can be listed as: powder, granular, ingot, rod, plate, block. The solid content in the solid oral composition of the present invention is usually 90% by mass or more, preferably 93% by mass or more, more preferably 95% by mass or more, and further preferably 97% by mass or more. In addition, there is no particular limitation on the upper limit of the solid content, and it can also be 100% by mass. Here, in this specification, "solid content" refers to the mass of the remainder obtained by drying the sample in an electric constant temperature dryer at 105°C for 3 hours and removing volatile substances.

[0043] Examples of the solid oral composition of the present invention include foods, pharmaceuticals, and quasi-drugs. Among them, solid foods are preferred, and powdered foods are more preferred, from the perspective of making it easy to enjoy the effects of the present invention.

[0044] When the solid oral composition of the present invention is a solid food, for example, it may be sweets such as maltose, candy, chewing gum, chocolate, biscuits and bread; health, beauty, and nutritional supplements such as supplements.

[0045] In addition, when the solid oral composition of the present invention is a pharmaceutical product or a quasi-drug, its dosage form includes, for example, granules, powders, tablets, pills, chewable tablets, lozenges, etc. In addition, when it is made into tablets, it can also be made into split tablets with cut lines.

[0046] Among them, as a solid oral composition, a supplement, a powder, a tablet, and a granule are preferable.

[0047] The solid oral composition of the present invention may contain an acceptable carrier as needed to form a solid form. For example, the following can be cited: excipients (e.g., starches such as corn starch (corn), potato starch (potato), sugarcane starch (sweet potato), tapioca starch, etc.); dextrin; sugar alcohols such as xylitol, sorbitol, maltitol, lactitol, reduced palatinose, trehalose, palatinose, etc.; lactose; oligosaccharides; crystalline cellulose; light anhydrous silicic acid; calcium hydrogen phosphate, etc.), binders (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan, methylcellulose, hydrogenated oil, etc.), disintegrants (e.g., carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone), lubricants (e.g., calcium stearate, magnesium stearate, sucrose fatty acid ester, sodium stearyl fumarate, talc, silica, etc.), fluidity improvers, flavoring agents (e.g., stevia, etc.), bulking agents, surfactants, dispersants, buffering agents, antioxidants, preservatives, quality stabilizers, diluents, etc. As the carrier, it is preferable to select a carrier that does not have an unpleasant odor. For example, as the excipient, from the aspect of not having an unpleasant odor, dextrin, maltitol, and lactose are preferably used.

[0048] In addition, the solid oral composition of the present invention can also be made into an instant beverage composition. Here, in this specification, the "instant beverage composition" refers to a beverage composition that is orally ingested as a reconstituted beverage by diluting with a liquid according to a specified usage. The liquid is not particularly limited as long as it can be reconstituted into a beverage. For example, water, carbonated water, milk, soy milk, etc. can be cited, and there is no limit to the temperature of the liquid. In addition, regarding the dilution ratio, it can be determined according to the specified usage, and is usually 30 to 800 mass times, preferably 80 to 600 mass times.

[0049] In addition, when the oral composition of the present invention is in the form of a solid or concentrate such as an instant beverage composition, after being diluted at a specified dilution rate, it satisfies the contents of the above-mentioned component (A) and component (B), and preferably the mass ratio [(B) / (A)] satisfies the above-mentioned requirements.

[0050] The solid oral composition of the present invention can be manufactured by a conventional method and an appropriate method can be adopted. For example, the components (A) and (B), and other components contained as needed can be mixed in such a manner that the contents of the components (A) and (B) are within the above ranges for manufacturing. There is no particular limitation on the mixing order of the component (A) and the component (B). One component can be added to the other component, or the two components can be added simultaneously. As the mixing method, appropriate methods such as stirring and shaking can be adopted, or a mixing device can be used. The mixing mode of the mixing device can be a container rotation type or a container fixed type. As the container rotation type, for example, a horizontal cylindrical type, a V type, a double cone type, a cubic type, etc. can be adopted. In addition, as the container fixed type, for example, a belt type, a screw type, a conical screw type, a paddle type, a fluidized bed type, a Philips mixer, etc. can be adopted.

[0051] In addition, the solid oral composition of the present invention can be made into granules by a known granulation method. As the granulation method, for example, spray granulation, fluidized bed granulation, compression granulation, rolling granulation, stirring granulation, extrusion granulation, powder coating granulation, etc. can be cited. In addition, the granulation conditions can be appropriately selected according to the granulation method. In addition, in the case of making a lozenge, it can be either wet tableting or dry tableting, and a known compression molding machine can be used.

[0052] The solid oral composition of the present invention can be filled into a package. As the package, for example, a bottle, a can, a box-shaped container, a stick-shaped package, a pillow-shaped package, etc. can be cited. In addition, when filling the solid oral composition of the present invention into a package, a commercially available filling machine can be used. The solid oral composition of the present invention can be, for example, packaged in small portions in an amount for one intake. When the solid oral composition is an instant beverage composition, for example, it can be made into any of the following: contained in a container such as a bottle, and measured with a spoon or the like in an amount equivalent to 1 cup when drinking; a cup type in which an amount equivalent to 1 cup is stored; and a stick type in which it is packaged in small portions in an amount equivalent to 1 cup per portion, etc.

[0053] In addition, nitrogen can be filled in the container and the packaging material. In addition, from the aspect of maintaining quality, the packaging material is preferably a packaging material with low oxygen permeability.

[0054] As long as the liquid oral composition of the present invention has fluidity at normal temperature (20°C ± 15°C), its form is not particularly limited. For example, a liquid, a concentrated liquid form, a gel form, a jelly form can be cited.

[0055] As the product form of the liquid oral composition of the present invention, for example, the following can be cited: RTD (Ready To Drink) type beverage compositions; instant beverage compositions; dairy products such as yogurt, processed milk, and fermented milk; oils and fat processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and sauces; seasonings such as sauces and dressings; health, beauty, and nutritional supplements such as beverages. Here, in the present specification, the "RTD type beverage composition" refers to a beverage that can be directly consumed without dilution.

[0056] Among them, as the liquid oral composition, an RTD type beverage composition is preferred. As the form of the RTD type beverage composition, for example, the following can be cited: liquid, concentrated liquid form, gel form, and jelly form. When the form is a concentrated liquid form, gel form, or jelly form, there is no particular limitation on the solid content concentration thereof, as long as the beverage composition can be sucked through a nozzle or a straw provided on the container.

[0057] From the viewpoint of flavor, the pH value (20 °C) of the RTD type beverage composition is preferably 3 or more, more preferably 3.5 or more, further preferably 4 or more, and additionally preferably 7 or less, more preferably 6.5 or less, and further preferably 6 or less. In addition, the pH value is the value measured by a pH meter after adjusting the temperature to 20 °C.

[0058] The RTD type beverage composition can be a non-alcoholic beverage or an alcoholic beverage. Here, in the present specification, the "non-alcoholic beverage" refers to a beverage with an alcohol concentration of less than 1 v / v%, and also includes beverages that completely do not contain alcohol and beverages with an alcohol concentration of 0.00 v / v%. In addition, in the present specification, unless otherwise specified, "alcohol" refers to ethanol.

[0059] As non-alcoholic beverages, for example, the following can be cited: tea beverages, carbonated beverages, fruit juice beverages, vegetable beverages, milk beverages, sports beverages, isotonic beverages, enhanced water, bottled water, watery beverages, nutritional beverages, beauty beverages, etc.

[0060] As alcoholic beverages, for example, the following can be cited: beer, wine, sake, plum wine, sparkling wine, whisky, brandy, distilled spirits, rum, gin, liqueurs, etc.

[0061] The RTD type beverage composition can be canned. There is no particular limitation on the container, as long as it is a common packaging container. For example, the following can be cited: a forming container mainly composed of polyethylene terephthalate (so-called PET bottle), a metal can, a paper container obtained by laminating a metal foil or a plastic film, a bottle, etc.

[0062] In the case where the RTD-type beverage composition is a canned beverage composition, it may have been heat-sterilized. There are no particular limitations on the heat-sterilization method, as long as it meets the conditions specified in the applicable regulations (the Food Sanitation Law in Japan).

[0063] The liquid oral composition of the present invention can be manufactured by a conventional method, and an appropriate method can be adopted. For example, it can be manufactured by mixing component (A), component (B), and other components contained as needed with a liquid in such a manner that the contents of component (A) and component (B) are within the above ranges. There are no particular limitations on the mixing order of component (A), component (B), and other components, and they can be added in any order. In addition, examples of the liquid include water, carbonated water, milk, and soy milk, and there is no limitation on the temperature of the liquid.

[0064] [Inhibitor of Unpleasant Odor of Branched Fatty Acids with 6 or Fewer Carbon Atoms and Method for Inhibiting Unpleasant Odor]

[0065] The inhibitor of unpleasant odor and the method for inhibiting unpleasant odor of the present invention use (B) at least one monoterpenoid alcohol selected from linalool and geraniol as an active ingredient, and are specifically used for inhibiting the unpleasant odor of (A) branched fatty acids with 6 or fewer carbon atoms. In addition, the specific compositions of (A) branched fatty acids with 6 or fewer carbon atoms and (B) at least one monoterpenoid alcohol selected from linalool and geraniol are as described above.

[0066] In the inhibitor of unpleasant odor and the method for inhibiting unpleasant odor of the present invention, as long as (A) branched fatty acids with 6 or fewer carbon atoms coexist with (B) at least one monoterpenoid alcohol selected from linalool and geraniol, in this case, from the viewpoint of inhibiting unpleasant odor, it is preferable to have (B) at least one monoterpenoid alcohol selected from linalool and geraniol at 0.05 mass ppm or more coexisting with (A) branched fatty acids with 6 or fewer carbon atoms at 0.01 mass ppm or more.

[0067] In addition, the inhibitor of unpleasant odor of the present invention can be applied not only to component (A), but also to oral products containing component (A).

[0068] There are no particular limitations on the oral product, as long as it is a product that can be orally ingested, and it can be liquid or solid. For example, examples include food and beverages, pharmaceuticals, or quasi-drugs containing component (A). Among them, food and beverages are preferred.

[0069] As food and drink products, for example, solid foods containing component (A), or beverages or instant beverages containing component (A) can be cited. In addition, food and drink products can be manufactured by conventional methods according to the types of food and drink products.

[0070] There is no particular limitation on the dosage forms of pharmaceuticals and quasi-drugs. For example, orally administrable preparations can be cited. For example, known dosage forms such as liquid preparations and syrups can be used. In addition, when formulating, known additives can be formulated. In addition, pharmaceuticals and quasi-drugs can be manufactured by conventional methods.

[0071] The respective contents of component (A) and component (B) and the mass ratio [(B) / (A)] in the oral products are as described above.

[0072] Regarding the above-described embodiments, the present invention further discloses the following oral compositions, inhibitors of the unpleasant odor of branched-chain fatty acids having 6 or less carbon atoms, and methods for inhibiting unpleasant odors.

[0073] <1> An oral composition, which contains the following components (A) and (B),

[0074] (A) Branched-chain fatty acids having 6 or less carbon atoms: 0.01 mass ppm or more;

[0075] (B) At least one monoterpenoid alcohol selected from linalool and geraniol: 0.05 mass ppm or more.

[0076] <2> The oral composition according to <1>, wherein component (A) is preferably one or more selected from isobutyric acid, 2-methylbutyric acid, and isovaleric acid, and more preferably isovaleric acid.

[0077] <3> The oral composition according to <1> or <2>, wherein component (A) is preferably an extract derived from one or more coffee beans selected from green coffee beans and lightly roasted coffee beans.

[0078] <4> The oral composition according to any one of <1> to <3>, wherein the content of component (A) is 0.01 mass ppm or more, preferably 0.05 mass ppm or more, more preferably 0.3 mass ppm or more, and preferably 30 mass ppm or less, more preferably 20 mass ppm or less, further preferably 12 mass ppm or less, and further more preferably 8 mass ppm or less.

[0079] <5> The oral composition according to any one of <1> to <3>, wherein the content of component (A) is 0.01 mass ppm or more, preferably 0.01 to 30 mass ppm, more preferably 0.01 to 20 mass ppm, still more preferably 0.05 to 12 mass ppm, and even more preferably 0.3 to 8 mass ppm.

[0080] <6> The oral composition according to any one of <1> to <5>, wherein the content of component (B) is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 8 mass ppm or more, still more preferably 80 mass ppm or more, and preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, still more preferably 1200 mass ppm or less.

[0081] <7> The oral composition according to any one of <1> to <5>, wherein the content of component (B) is 0.05 mass ppm or more, preferably 0.05 to 3000 mass ppm, more preferably 0.08 to 2000 mass ppm, still more preferably 8 to 2000 mass ppm, and even more preferably 80 to 1200 mass ppm.

[0082] <8> The oral composition according to any one of <1> to <5>, wherein component (B) is linalool, and its content is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 0.8 mass ppm or more, still more preferably 8 mass ppm or more, and even more preferably 80 mass ppm or more, and preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, still more preferably 1200 mass ppm or less.

[0083] <9> The oral composition according to any one of <1> to <5>, wherein component (B) is linalool, and its content is 0.05 mass ppm or more, preferably 0.05 to 3000 mass ppm, more preferably 0.08 to 2000 mass ppm, still more preferably 0.8 to 2000 mass ppm, and even more preferably 8 to 2000 mass ppm, and even more preferably 80 to 1200 mass ppm.

[0084] <10> The oral composition according to any one of <1> to <5>, wherein component (B) is geraniol, and its content is 0.05 mass ppm or more, preferably 0.08 mass ppm or more, more preferably 8 mass ppm or more, still more preferably 800 mass ppm or more, and preferably 3000 mass ppm or less, more preferably 2000 mass ppm or less, still more preferably 1500 mass ppm or less.

[0085] <11> The oral composition according to any one of <1> to <5>, wherein the component (B) is geraniol, and its content is 0.05 mass ppm or more, preferably 0.05 to 3000 mass ppm, more preferably 0.08 to 2000 mass ppm, still more preferably 8 to 2000 mass ppm, and even more preferably 800 to 1500 mass ppm.

[0086] <12> The oral composition according to any one of <1> to <11>, wherein the mass ratio [(B) / (A)] of the component (B) to the component (A) is preferably 0.003 or more, more preferably 0.15 or more, still more preferably 15 or more, and even more preferably 100 or more. In addition, it is preferably 20000 or less, more preferably 16000 or less, and still more preferably 12000 or less.

[0087] <13> The oral composition according to any one of <1> to <11>, wherein the mass ratio [(B) / (A)] of the component (B) to the component (A) is preferably 0.003 to 20000, more preferably 0.15 to 20000, still more preferably 15 to 16000, and even more preferably 100 to 12000.

[0088] <14> The oral composition according to any one of <1> to <9>, wherein the component (B) is linalool, and the mass ratio [linalool / (A)] of linalool to the component (A) is preferably 0.003 or more, more preferably 0.15 or more, still more preferably 1 or more, and even more preferably 15 or more, and even more preferably 80 or more, and even more preferably 150 or more. In addition, it is preferably 20000 or less, more preferably 16000 or less, still more preferably 12000 or less, and even more preferably 6000 or less, and even more preferably 3000 or less.

[0089] <15> The oral composition according to any one of <1> to <9>, wherein the component (B) is linalool, and the mass ratio [linalool / (A)] of linalool to the component (A) is preferably 0.003 to 20000, more preferably 0.15 to 20000, still more preferably 1 to 20000, and even more preferably 15 to 16000, and even more preferably 80 to 12000, and even more preferably 80 to 6000, and even more preferably 150 to 3000.

[0090] <16> The oral composition according to any one of <1> to <7>, <10>, and <11>, wherein the component (B) is geraniol, and the mass ratio of geraniol to component (A) [geraniol / (A)] is preferably 0.003 or more, more preferably 0.15 or more, further preferably 1 or more, still more preferably 15 or more, still more preferably 100 or more, and preferably 20000 or less, more preferably 16000 or less, further preferably 12000 or less, still more preferably 6000 or less, still more preferably 3000 or less.

[0091] <17> The oral composition according to any one of <1> to <7>, <10>, and <11>, wherein the component (B) is geraniol, and the mass ratio of geraniol to component (A) [geraniol / (A)] is preferably 0.003 to 20000, more preferably 0.15 to 20000, further preferably 1 to 16000, still more preferably 15 to 12000, still more preferably 15 to 6000, still more preferably 100 to 3000.

[0092] <18> The oral composition according to any one of <1> to <17>, wherein the oral composition is preferably a solid oral composition or a liquid oral composition.

[0093] <19> The oral composition according to any one of <1> to <18>, wherein the oral composition is preferably an instant beverage composition.

[0094] <20> The oral composition according to any one of <1> to <19>, wherein the oral composition is preferably an oral composition other than a coffee beverage.

[0095] <21> The oral composition according to any one of <1> to <20>, wherein the content of (C) furfuryl mercaptan is preferably less than 0.00006% by mass, more preferably less than 0.00003% by mass, further preferably less than 0.00001% by mass, and still more preferably substantially free of (C) furfuryl mercaptan.

[0096] <22> The oral composition according to any one of <1> to <21>, wherein the oral composition is an oral composition other than a coffee beverage, and the coffee beverage is prepared using roasted coffee beans including roasted coffee beans with an L value preferably less than 30, more preferably less than 32, further preferably less than 34, still more preferably less than 36, still more preferably less than 38, and still more preferably less than 40.

[0097] <23>An inhibitor of the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms, wherein at least one monoterpenol selected from linalool and geraniol is used as an active ingredient.

[0098] <24>A method for inhibiting the unpleasant odor of a branched-chain fatty acid having 6 or less carbon atoms, wherein at least one monoterpenol selected from linalool and geraniol coexists with the branched-chain fatty acid having 6 or less carbon atoms.

[0099] <25>The inhibitor of the unpleasant odor as described in <23>, or the method for inhibiting the unpleasant odor as described in <24>, wherein the branched-chain fatty acid having 6 or less carbon atoms is preferably one or more selected from isobutyric acid, 2-methylbutyric acid, and isovaleric acid, and more preferably isovaleric acid.

[0100] <26>The inhibitor of the unpleasant odor or the method for inhibiting the unpleasant odor as described in any one of <23> to <25>, wherein the branched-chain fatty acid having 6 or less carbon atoms is preferably an extract derived from one or more coffee beans selected from raw coffee beans and lightly roasted coffee beans.

[0101] <27>The inhibitor of the unpleasant odor or the method for inhibiting the unpleasant odor as described in any one of <23> to <26>, wherein the mass ratio of the monoterpenol to the branched-chain fatty acid having 6 or less carbon atoms [monoterpenol / branched-chain fatty acid having 6 or less carbon atoms] is preferably 0.15 or more, more preferably 15 or more, further preferably 100 or more, and preferably 20000 or less, more preferably 16000 or less, further preferably 12000 or less.

[0102] [Examples]

[0103] (1) Analysis of branched-chain fatty acids

[0104] Analysis can be performed by a third-party organization using the GC / MS method or the HPLC method. For analysis by the GC / MS method, it can be entrusted to the Japan Food Analysis Center, a juridical person. Additionally, for analysis by the HPLC method, it can be entrusted to Shimadzu Techno-Research Co., Ltd.

[0105] (2) Analysis of linalool and geraniol

[0106] Analysis can be performed by a third-party organization using the GC / MS method and can be entrusted to the Japan Food Analysis Center, a juridical person.

[0107] Examples 1 to 5 and Comparative Examples 1 to 2

[0108] Iso-valeric acid and linalool were dissolved in 99.5% ethanol (manufactured by FUJIFILM Wako Pure Chemical Corporation) at respective concentrations, and 1 g of maltitol powder (LESYS fine powder; manufactured by Mitsubishi Corporation Life Sciences) was mixed with 100 μL of the ethanol solution. The concentration of the ethanol solution was adjusted to achieve the final concentrations shown in Table 2. It was left standing at 50°C for 10 minutes to allow the ethanol to evaporate, thereby preparing a powdery oral composition. Each oral composition was analyzed and subjected to sensory evaluation. The results are shown together in Table 2.

[0109] [Sensory evaluation]

[0110] Regarding the "intensity of the unpleasant odor of iso-valeric acid" of the powdery oral compositions obtained in each example and comparative example, two professional sensory inspectors conducted a sensory test in the following order. First, "iso-valeric acid standard powder" was prepared using an iso-valeric acid reagent, and its concentration was pre-adjusted so that the intensity of the "unpleasant odor of iso-valeric acid" was divided into five grades at equal intervals. The "iso-valeric acid standard powder" was prepared by dissolving iso-valeric acid in 99.5% ethanol (manufactured by FUJIFILM Wako Pure Chemical Corporation) at respective concentrations, and 1 g of maltitol powder (LESYS fine powder; manufactured by Mitsubishi Corporation Life Sciences) was mixed with 100 μL of the ethanol solution. The concentration of the ethanol solution was adjusted to achieve the final concentrations shown in Table 1. It was left standing at 50°C for 10 minutes to allow the ethanol to evaporate, and then the odor was evaluated by two professional sensory inspectors. Regarding the evaluation, each professional sensory inspector agreed to record the intensity of the unpleasant odor of iso-valeric acid at each concentration as the score shown in Table 1. Next, each professional sensory inspector evaluated the "iso-valeric acid standard powder" in sequence starting from the sample with a lower iso-valeric acid concentration and memorized the "intensity of the unpleasant odor of iso-valeric acid". Then, each professional sensory inspector evaluated the degree of the "intensity of the unpleasant odor of iso-valeric acid" when ingesting the test oral composition and determined the one with the closest "intensity of the unpleasant odor of iso-valeric acid" from the "iso-valeric acid standard powder". Then, based on the scores determined by each professional sensory inspector, the final score was determined through consultation. In addition, the smaller the numerical value of the score, the weaker the intensity of the unpleasant odor of iso-valeric acid.

[0111] [Table 1]

[0112] Iso-valeric acid standard powder

[0113] Score Composition Intensity of the unpleasant odor of isovaleric acid 5 Isovaleric acid: 5 mass ppm Feels relatively strong 4 Isovaleric acid: 0.5 mass ppm Feels 3 Isovaleric acid: 0.1 mass ppm Feels slightly 2 Isovaleric acid: 0.01 mass ppm Feels very little 1 Isovaleric acid: 0 mass ppm Can't feel at all

[0114] [Table 2]

[0115]

[0116] *1 Iso-valeric acid: FUJIFILM Wako Pure Chemical Corporation

[0117] *2 Linalool: FUJIFILM Wako Pure Chemical Corporation

[0118] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0119] Examples 6 to 10 and Comparative Examples 3 to 4

[0120] By the same operation as in Example 1, powdery oral compositions having the compositions shown in Table 3 were obtained. Each oral composition was analyzed and subjected to sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 1. The results are shown together in Table 3.

[0121] [Table 3]

[0122]

[0123] *1 Isovaleric acid: FUJIFILM Wako Pure Chemical Corporation

[0124] *2 Linalool: FUJIFILM Wako Pure Chemical Corporation

[0125] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0126] Examples 11 to 15 and Comparative Examples 5 to 6

[0127] By the same operation as in Example 1, powdery oral compositions having the compositions shown in Table 4 were obtained. Each oral composition was analyzed and subjected to sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 1. The results are shown together in Table 4.

[0128] [Table 4]

[0129]

[0130] *1 Isovaleric acid: FUJIFILM Wako Pure Chemical Corporation

[0131] *2 Linalool: FUJIFILM Wako Pure Chemical Corporation

[0132] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0133] Examples 16 to 20 and Comparative Examples 7 to 8

[0134] Using geraniol instead of linalool, by the same operation as in Example 1, powdery oral compositions having the compositions shown in Table 5 were obtained. Each oral composition was analyzed and subjected to sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 1. The results are shown together in Table 5.

[0135] [Table 5]

[0136]

[0137] *1 Isovaleric acid: FUJIFILM Wako Pure Chemical Corporation

[0138] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0139] *4 Geraniol: FUJIFILM Wako Pure Chemical Corporation

[0140] Examples 21 to 24 and Comparative Examples 9 to 10

[0141] Through the same operations as in Example 16, powdery oral compositions having the compositions shown in Table 6 were obtained. Each oral composition was analyzed and subjected to sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 1. The results are shown together in Table 6.

[0142] [Table 6]

[0143]

[0144] *1 Isovaleric acid: FUJIFILM Wako Pure Chemical Corporation

[0145] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0146] *4 Geraniol: FUJIFILM Wako Pure Chemical Corporation

[0147] Examples 25 to 28 and Comparative Examples 11 to 12

[0148] Through the same operations as in Example 16, powdery oral compositions having the compositions shown in Table 7 were obtained. Each oral composition was analyzed and subjected to sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 1. The results are shown together in Table 7.

[0149] [Table 7]

[0150]

[0151] *1 Isovaleric acid: FUJIFILM Wako Pure Chemical Corporation

[0152] *3 Maltitol: Mitsubishi Corporation Life Science, Ltd.

[0153] *4 Geraniol: FUJIFILM Wako Pure Chemical Corporation

[0154] Examples 29 to 33 and Comparative Examples 13 to 14

[0155] Isobutyric acid and linalool were dissolved in 99.5% ethanol (manufactured by FUJIFILM Wako Pure Chemical Corporation) at various concentrations, and 1 g of maltitol powder (LESYS fine powder; manufactured by Mitsubishi Corporation Life Science) was mixed with 100 μL of the ethanol solution. The concentration of the ethanol solution was adjusted to achieve the final concentrations shown in Table 9. The mixture was allowed to stand at 50 °C for 10 minutes to evaporate the ethanol, thereby preparing a powdery oral composition. Each oral composition was analyzed and subjected to a sensory evaluation. The results are shown together in Table 9.

[0156] [Sensory evaluation]

[0157] Regarding the "intensity of the unpleasant odor of isobutyric acid" of the powdery oral compositions obtained in each example and comparative example, a professional sensory inspector adjusted the concentration of the ethanol solution to achieve the final concentrations shown in Table 9 using an isobutyric acid reagent, and otherwise, conducted a sensory test in the same order as the "intensity of the unpleasant odor of isovaleric acid" described above to determine the final score. In addition, since the olfactory threshold of isobutyric acid is higher than that of isovaleric acid, the concentration of the standard sample was adjusted to achieve an odor intensity similar to that of isovaleric acid.

[0158] The smaller the numerical value of the score, the weaker the intensity of the unpleasant odor of isobutyric acid.

[0159] [Table 8]

[0160] Isobutyric acid standard powder

[0161] Score Composition Intensity of the unpleasant odor of isobutyric acid 5 Isobutyric acid: 100 mass ppm Feels relatively strong 4 Isobutyric acid: 50 mass ppm Feels 3 Isobutyric acid: 20 mass ppm Feels slightly 2 Isobutyric acid: 10 mass ppm Feels very little 1 Isobutyric acid: 0 mass ppm Can't feel at all

[0162] [Table 9]

[0163]

[0164] *2 Linalool: FUJIFILM Wako Pure Chemical Corporation

[0165] *3 Maltitol: Mitsubishi Corporation Life Science

[0166] *5 Isobutyric acid: FUJIFILM Wako Pure Chemical Corporation

[0167] Examples 34 to 38 and Comparative Examples 15 to 16

[0168] Geraniol was used instead of linalool, and by the same operation as in Example 29, a powdery oral composition having the composition shown in Table 10 was obtained. Each oral composition was analyzed and subjected to a sensory evaluation. In the sensory evaluation, the evaluation was conducted in the same manner as in Example 29. The results are shown together in Table 10.

[0169] [Table 10]

[0170]

[0171] * 3 Maltitol: Mitsubishi Corporation Life Sciences, Ltd.

[0172] * 4 Geraniol: FUJIFILM Wako Pure Chemical Corporation

[0173] * 5 Isobutyric acid: FUJIFILM Wako Pure Chemical Corporation

[0174] Examples 39 to 43 and Comparative Examples 17 to 18

[0175] 2-Methylbutyric acid and linalool were dissolved in 99.5% ethanol (manufactured by FUJIFILM Wako Pure Chemical Corporation) at each concentration, and 1 g of maltitol powder (LESYS fine powder; manufactured by Mitsubishi Corporation Life Sciences, Ltd.) was mixed with 100 μL of the ethanol solution. The concentration of the ethanol solution was adjusted to achieve the final concentration shown in Table 12. It was left standing at 50 °C for 10 minutes to evaporate the ethanol, thereby preparing a powdery oral composition. Each oral composition was analyzed and subjected to a sensory evaluation. The results are shown together in Table 12.

[0176] [Sensory evaluation]

[0177] Regarding the "intensity of the unpleasant odor of 2-methylbutyric acid" of the powdery oral compositions obtained in each example and comparative example, a professional sensory inspector adjusted the concentration of the ethanol solution to achieve the final concentration shown in Table 11 using a 2-methylbutyric acid reagent, and otherwise, conducted a sensory test in the same order as the above "intensity of the unpleasant odor of isovaleric acid" to determine the final score. In addition, since the olfactory threshold of 2-methylbutyric acid is higher than that of isovaleric acid, the concentration of the standard sample was adjusted to achieve an odor of the same level as isovaleric acid.

[0178] The smaller the numerical value of the score, the weaker the intensity of the unpleasant odor of 2-methylbutyric acid.

[0179] [Table 11]

[0180] 2-Methylbutyric acid standard powder

[0181] Score Composition Intensity of the unpleasant odor of 2-methylbutyric acid 5 2-Methylbutyric acid: 100 mass ppm Feels relatively strong 4 2-Methylbutyric acid: 50 mass ppm Feels 3 2-Methylbutyric acid: 20 mass ppm Feels slightly 2 2-Methylbutyric acid: 10 mass ppm Feels very little 1 2-Methylbutyric acid: 0 mass ppm Can't feel at all

[0182] [Table 12]

[0183]

[0184] * 2 Linalool: FUJIFILM Wako Pure Chemical Corporation

[0185] * 3 Maltitol: Mitsubishi Corporation Life Sciences, Ltd.

[0186] *6 2-Methylbutyric acid: FUJIFILM Wako Pure Chemical Corporation

[0187] Examples 44 to 48 and Comparative Examples 19 to 20

[0188] Using geraniol instead of linalool, by the same operation as in Example 39, a powdery oral composition having the composition shown in Table 13 was obtained. Each oral composition was analyzed and subjected to a sensory evaluation. In the sensory evaluation, the evaluation was carried out in the same manner as in Example 39. The results are shown together in Table 13.

[0189] [Table 13]

[0190]

[0191] *3 Maltitol: Mitsubishi Corporation Life Sciences

[0192] *4 Geraniol: FUJIFILM Wako Pure Chemical Corporation

[0193] *6 2-Methylbutyric acid: FUJIFILM Wako Pure Chemical Corporation

[0194] From Tables 2 to 13, it can be seen that by containing a specified amount or more of linalool and / or geraniol, an oral composition in which the unpleasant odors of isovaleric acid, isobutyric acid, and 2-methylbutyric acid are suppressed can be obtained.

Claims

1. An oral composition, wherein: it contains the following components (A) and (B); (A) A branched fatty acid having 6 or less carbon atoms: 0.01 mass ppm or more; (B) At least one monoterpenol selected from linalool and geraniol: 0.05 mass ppm or more.

2. The oral composition according to claim 1, wherein: the mass ratio (B) / (A) of component (B) to component (A) is 0.003 to 20000.

3. The oral composition according to claim 1 or 2, wherein: the content of component (A) is 0.01 to 30 mass ppm.

4. The oral composition according to any one of claims 1 to 3, wherein: the content of component (B) is 0.05 to 3000 mass ppm.

5. The oral composition according to any one of claims 1 to 4, wherein: component (A) is one or more selected from isobutyric acid, 2-methylbutyric acid and isovaleric acid.

6. An inhibitor for the unpleasant odor of a branched fatty acid having 6 or less carbon atoms, wherein: at least one monoterpenol selected from linalool and geraniol is used as an active ingredient.

7. A method for inhibiting the unpleasant odor of a branched fatty acid having 6 or less carbon atoms, wherein: at least one monoterpenol selected from linalool and geraniol coexists with a branched fatty acid having 6 or less carbon atoms.

8. The unpleasant odor inhibitor according to claim 6, or the unpleasant odor inhibition method according to claim 7, wherein: the branched fatty acid having 6 or less carbon atoms is one or more selected from isobutyric acid, 2-methylbutyric acid and isovaleric acid.

Images